PLoS ONE (Jan 2019)

Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection.

  • Pierre Gantner,
  • Laurent Cotte,
  • Clotilde Allavena,
  • Firouzé Bani-Sadr,
  • Thomas Huleux,
  • Claudine Duvivier,
  • Marc-Antoine Valantin,
  • Christine Jacomet,
  • Véronique Joly,
  • Antoine Chéret,
  • Pascal Pugliese,
  • Pierre Delobel,
  • André Cabié,
  • David Rey,
  • Dat’AIDS Study Group

DOI
https://doi.org/10.1371/journal.pone.0215464
Journal volume & issue
Vol. 14, no. 4
p. e0215464

Abstract

Read online

IntroductionAchieving functional cure of chronic HBV infection (Hepatitis B surface antigen [HBsAg] clearance, eventually followed by acquisition of anti-hepatitis B surface antigen [Anti-HBs]) in individuals with HIV and HBV infections is a rare event. In this setting, factors related to HBV cure have not yet been fully characterized.MethodsHIV-infected individuals with chronic HBV infection enrolled in the French Dat'AIDS cohort (NCT02898987), who started combined antiretroviral (cART)-anti-HBV treatment were retrospectively analyzed for HBsAg loss and Anti-HBs seroconversion.ResultsOverall, 1419 naïve-subjects received three different cART-anti-HBV treatment schedule: (1) 3TC or FTC only (n = 150), (2) TDF with or without 3TC or FTC (n = 489) and (3) 3TC or FTC as first line followed by adding/switching to TDF as second line (n = 780). Individuals were followed-up for a median of 89 months (IQR, 56-118). HBV-DNA was 1, >95%) suggested by Bayesian analysis. Also, TDF-based regimen as first line (OR, 3.03) or second line (OR, 2.95) increased rates of HBsAg clearance compared to 3TC or FTC alone, with a 99% probability.ConclusionsHBsAg clearance rate was low in HIV-HBV co-infected cART-anti-HBV treated individuals, but was slightly improved on TDF-based regimen.